Literature DB >> 1723716

Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

T Seya1, M Okada, T Hara, M Matsumoto, S Miyagawa, M Oshimura.   

Abstract

The structural genes of human complement regulatory proteins are clustered on chromosome 1 at position q3.2. Human chromosome 1 was transferred into a mouse fibroblast cell line, A9 [designated as A9(neo-1)], and the surface expression of its gene products participating in complement regulation, namely C3b/C4b receptor (CR1, CD35), decay-accelerating factor (DAF, CD55), membrane co-factor protein (MCP, CD46) and C3d/EB virus receptor (CR2, CD21), were assessed using respective monoclonal antibodies by flow cytometry. CR1 became positive within 7 days of culture. MCP appeared in a small population of cells by Day 3 and, together with DAF, began to increase on Day 7. CR2 appeared on Day 14. The order of the expression was CR1 greater than DAF = MCP greater than CR2. On Day 42, however, all became negative except for MCP, which was markedly diminished. These human regulatory proteins were specifically associated with the presence of human chromosome 1, since none of them were expressed on human chromosome 12-transferred A9 cells [A9(neo-12)]. Intact A9 and A9(neo-12) cells activated human complement via the alternative pathway. The activation of this pathway was suppressed in the A9(neo-1) cells that expressed CR1, DAF and MCP. Slight protective activity was still observed in the 42-day cultured A9(neo-1) cells expressing only trace MCP. These results suggest that human complement regulators, expressed via the transferred human chromosome 1, can protect heterologous cells from complement, overcoming their ability to activate the human alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723716      PMCID: PMC1384786     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

Review 1.  Activation of the alternative complement pathway.

Authors:  D T Fearon
Journal:  CRC Crit Rev Immunol       Date:  1979-11

2.  Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.

Authors:  V Caudwell; F Porteu; A Calender; M K Pangburn; L Halbwachs-Mecarelli
Journal:  Eur J Immunol       Date:  1990-12       Impact factor: 5.532

3.  Application of protein A-rosette assay for screening of monoclonal antibodies to human complement regulatory proteins.

Authors:  T Seya; T Hara; A Uenaka; E Nakayama; H Akedo
Journal:  Complement Inflamm       Date:  1990

4.  Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.

Authors:  T Seya; T Hara; M Matsumoto; H Akedo
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

5.  Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.

Authors:  M Matsumoto; Y Sugita; T Seya
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

6.  Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.

Authors:  E Fischer; M D Kazatchkine
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).

Authors:  T Seya; T Hara; M Matsumoto; Y Sugita; H Akedo
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

8.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

9.  Construction of mouse A9 clones containing a single human chromosome tagged with neomycin-resistance gene via microcell fusion.

Authors:  M Koi; M Shimizu; H Morita; H Yamada; M Oshimura
Journal:  Jpn J Cancer Res       Date:  1989-05

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  1 in total

1.  Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects.

Authors:  T Hara; S Kuriyama; H Kiyohara; Y Nagase; M Matsumoto; T Seya
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.